Research progress on anti-vascular endothelial growth factor prognostic biomarkers for macular edema secondary to retinal vein occlusion
10.3980/j.issn.1672-5123.2025.12.07
- VernacularTitle:视网膜静脉阻塞继发黄斑水肿抗VEGF预后生物标志物研究进展
- Author:
Dan WANG
1
;
Xiaofeng HAO
1
;
Like XIE
1
;
Xiangdong CHEN
1
;
Jing XU
1
;
Mei SUN
1
;
Mengjiao ZHANG
1
;
Xiaoduo GUAN
1
Author Information
1. Eye Hospital China Academy of Chinese Medical Sciences, Beijing 100040, China
- Publication Type:Journal Article
- Keywords:
retinal vein occlusion;
macular edema;
prognosis;
biomarkers;
anti-vascular endothelial growth factor(VEGF)
- From:
International Eye Science
2025;25(12):1938-1942
- CountryChina
- Language:Chinese
-
Abstract:
Retinal vein occlusion(RVO)is the second most common blinding retinal vascular disease, and its secondary macular edema(ME)is an important cause of visual function impairment in patients. Intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs serves as the first-line treatment, yet it is confronted with such issues as the need for repeated injections and non-response in some patients. Imaging and laboratory biomarkers play a crucial role in the early accurate diagnosis, prediction of disease progression, and evaluation of visual prognosis of RVO-ME. This study systematically reviews the research progress of imaging and laboratory biomarkers related to the prognosis of RVO-ME after anti-VEGF treatment in recent years, covering imaging biomarkers like central retinal thickness and ellipsoid zone integrity, as well as laboratory biomarkers such as serum APLN and aqueous humor IL-6. It summarizes the associations between different biomarkers and the prognosis of anti-VEGF therapy, aiming to provide a basis for the early accurate assessment and optimization of individualized treatment for RVO-ME patients, which holds significant clinical reference value.
